The authors' previous study demonstrated that the B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (BCL2L11) (Bim) deletion polymorphism was associated with poor clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC) with EGFR mutations. The objective of the current study was to investigate the impact of the Bim deletion polymorphism among patients with anaplastic lymphoma kinase (ALK)-positive or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)-positive NSCLC who were treated with crizotinib. METHODS: A total of 55 patients with ALK-positive NSCLC and 14 patients with ROS1-positive NSCLC who were treated with crizotinib were enrolled into the current study. The Bim deletion polymorphism was analyzed by polymerase chain reaction. The clinical features of the Bim deletion polymorphism and its impact on the effect of crizotinib were investigated. RESULTS: The Bim deletion polymorphism was present in 9 of 69 patients with ALK-positive or ROS1-positive NSCLC (13.0%). There were no differences noted with regard to clinicopathological features between patients with and without the Bim deletion polymorphism. Patients with the Bim deletion polymorphism had a significantly shorter progression-free survival (PFS) and lower objective response rate compared with those without (median PFS, 182 days vs 377 days [P 5 .008]) (objective response rate, 44.4% vs 81.7% [P 5.041]) in all populations. The significant difference in PFS was observed in patients with ALK-positive NSCLC (83 days vs 305 days [P 5.0304]) compared with those with ROS1-positive NSCLC (218 days vs not reached [P 5.082]). Multivariate analysis indicated that the Bim deletion polymorphism was an independent predictive factor for patients with ALK-positive NSCLC who were treated with crizotinib (hazard ratio, 4.786 [P 5.006]). CONCLU-SIONS: The Bim deletion polymorphism was found to be associated with poor clinical response to crizotinib in patients with ALK fusion-positive NSCLC.
INTRODUCTION
Anaplastic lymphoma kinase (ALK) rearrangement represents a distinct molecular subgroup of non-small cell lung cancer (NSCLC) and accounts for approximately 3% to 7% of all NSCLC cases. [1] [2] [3] With the introduction of ALK tyrosine kinase inhibitors (TKIs), the therapeutic landscape for patients with ALK fusion-positive NSCLC has rapidly changed within the past few years. [4] [5] [6] [7] [8] [9] [10] Crizotinib, which to our knowledge is the first small molecule inhibitor targeting ALK to be tested in the clinic, 1 is superior to cytotoxic chemotherapy in patients with this subtype of NSCLC. 5, 7 However, approximately 30% of patients with ALK-positive disease demonstrate primary resistance to treatment with crizotinib. [11] [12] [13] Although the efficacy of crizotinib is remarkable, the majority of patients with ALK-positive NSCLC inevitably will develop a disease recurrence while receiving therapy within 1 to 2 years due to the emergence of acquired resistance. Acquired resistance is mediated by multiple different mechanisms, including secondary mutations in the ALK kinase domain and upregulation of bypass signaling pathways. [14] [15] [16] [17] [18] [19] [20] However, to the best of our knowledge, the mechanisms of primary resistance remain elusive.
The Bim protein is a proapoptotic member of the Bcell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) family of proteins, binding to the prosurvival Bcl-2 family members with high affinity and directly activating proapoptotic BAX and BAK to promote cell death. [21] [22] [23] In lung cancer cells that are positive for echinoderm microtubule-associated protein-like 4 (EML4)-ALK, Bim upregulation was required for the induction of apoptosis under ALK inhibitor treatment. 24, 25 In patients with epidermal growth factor receptor (EGFR)-mutant NSCLC, several previous studies have demonstrated that Bim deletion polymorphism was associated with a shorter progression-free survival (PFS) after treatment with EGFR-TKIs. [26] [27] [28] Moreover, Ng et al found that the Bim deletion polymorphism plays a crucial role in primary resistance to EGFR-TKI therapy. 29 However, to the best of our knowledge, the correlation between the Bim deletion polymorphism and the efficacy of crizotinib against ALK-positive or ROS1-positive NSCLC remains unknown. Therefore, the purpose of the current study was to investigate the clinical features of the Bim deletion polymorphism and its association with the effect of crizotinib in Chinese patients with ALK-positive or ROS1-positive NSCLC.
MATERIALS AND METHODS

Patients and Samples
Patients who were ALK fusion positive or ROS1 fusion positive as detected by reverse transcriptase-polymerase chain reaction (RT-PCR) assay at Shanghai Pulmonary Hospital of the Tongji University School of Medicine were considered to be eligible and therefore were enrolled into the current study. Pathological diagnosis and staging was carried out according to the staging system of the 2009 International Association for the Study of Lung Cancer (version 7). Their clinical data included age, sex, smoking status, histological type, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and previous treatment regimens. Nonsmokers were defined as patients with a smoking history of <100 cigarettes within their lifetime, and smokers were defined as patients with a smoking history of >100 cigarettes within their lifetime (including former and current smokers). Clinical responses were evaluated 1 month after the first administration of crizotinib (at a dose of 250 mg twice daily) and then every 2 cycles thereafter using a computed tomography scan according to Response Evaluation Criteria In Solid Tumors (RECIST; version 1.1). PFS was measured from the day crizotinib treatment was initiated until disease progression or death. Each patient provided written informed consent before the initiation of any study-related procedure. This study was approved by the Shanghai Pulmonary Hospital Ethics Committee.
RNA Preparation and Detection of ALK Rearrangements
All the samples were validated by pathologists. For the formalin-fixed and paraffin-embedded samples, all samples were evaluated by pathologists to confirm the presence of >30% tumor cells in the samples. For the cytological samples, once the operator obtained the tumor biopsy tissue, it was separated into 3 parts immediately: 1 part for pathologic analysis, 1 part for extracting DNA, and the third part was placed directly into an RNase-free Eppendorf tube containing 500 lL of RNAlater (Life Technologies, Gaithersburg, Md) and stored at -808C and preserved for extracting mRNA. RNA from tissue samples was extracted using either the RNeasy Mini Kit (Qiagen, Hilden, Germany) or AmoyDx RNA Kit (Amoy Diagnostics Co Ltd, Xiamen, China) according to the manufacturer's protocol. The Amplification Refractory Mutation System (ARMS) was adopted to detect ALK fusion and ROS1 fusion using the Human AmoyDx EML4-ALK Fusion Gene Diagnostic Kit and the Human AmoyDx ROS1 Fusion Gene Diagnostic Kit (Amoy Diagnostics Co, Ltd), respectively. The details were provided in our previous studies. [30] [31] [32] [33] [34] [35] DNA Extraction and Genotyping of the Bim Deletion Polymorphism DNA from peripheral blood or tumor tissue was extracted using the DNeasy Blood and Tissue Kit or the QIAamp DNA FFPE Tissue Kit (both from Qiagen) as per the standard protocols. All samples were amplified by PCR to detect the Bim deletion polymorphism. The primer sequences and reaction conditions were performed according to the methods used in our previous study and provided in detail there. 27 The PCR products (173 base pairs for deleted Bim and 216 base pairs for wild-type Bim) were analyzed on 2% agarose gels.
Statistical Analysis
All analyses were performed using SPSS statistical software (version 22.0; IBM Corporation, Armonk, NY). The chi-square test or Fisher exact test was used to compare the categorical variables. The Kaplan-Meier method was used to calculate the PFS, and the log-rank test was
Original Article performed to compare the PFS between the different groups. A Cox regression model was used to analyze independent factors. A P value <.05 was considered to be statistically significant in a 2-way analysis.
RESULTS
Detection of the Bim Deletion in Patients With
ALK-Positive or ROS1-Positive NSCLC The current retrospective study was performed to analyze the Bim deletion polymorphism in 69 patients with NSCLC with gene rearrangement who were treated with crizotinib, including 55 patients with ALK-positive and 14 patients with ROS1-positive disease. All patient characteristics are outlined in Table 1 . The median age of the patients was 51 years; 33 patients were men and 36 were women. The majority of patients were nonsmokers (78.3%) and had an ECOG PS of 0 to 1 (81.2%), stage IV disease (89.9%) with adenocarcinoma (94.2%), and had received 0 to 1 previous treatments (75.4%). Among 69 patients treated with crizotinib, 2 patients achieved a complete response, 51 achieved a partial response, 10 had stable disease, and 6 developed progressive disease. In addition, 9 of 69 patients (13.0%) were found to possess the Bim deletion polymorphism.
Bim Deletion Polymorphism Distribution
All patients with the Bim deletion polymorphism were heterozygous. PCR products of all samples were reconfirmed by direct sequencing. Electrophoretic and direct sequencing results are detailed in Figure 1 . Among 9 patients with the Bim deletion polymorphism, the median age was 51 years, 7 were women, and 8 were nonsmokers. All patients with the Bim deletion polymorphism had stage IV disease with adenocarcinoma, including 6 patients with the ALK gene rearrangement and 3 with the ROS1 gene rearrangement. Details regarding the patients with the Bim deletion polymorphism are outlined in Supporting Information Table s1 . In addition, there were no significant differences noted with regard to age (P 5 1.000), sex (P 5.197), smoking history (P 5.692), ECOG PS (P 5.858), histology (P 5 1.000), stage of disease (P 5.582), number of previous treatments (P 5 1.000), or gene rearrangement (P 5.549) between patients with (9 patients) and without (60 patients) the Bim deletion polymorphism (Table 2) .
Association Between the Bim Deletion Polymorphism and the Efficacy of Crizotinib
In the total population, the objective response rate (ORR) for patients with the Bim deletion polymorphism versus those without was 44.4% versus 81.7%, respectively (P 5.041), and the disease control rate was similar between the 2 groups (77.8% vs 93.3% [P 5 .171]) (Table 3) . However, 8 patients with ALK-positive and 3 patients with ROS1-positive disease without the Bim deletion polymorphism were lost to follow-up by the end of data collection in November 2016. For 58 patients with the ALK or ROS1 fusion gene, the median PFS was 305 days (95% confidence interval, 178.60-431.40 days). The median PFS for patients with the Bim deletion polymorphism was significantly shorter compared with that for patients without the Bim deletion polymorphism (median PFS, 182 days vs 377 days [P 5.008]) (Figs. 2a and 2b ). In the subgroup of patients with ALK-positive NSCLC, those with the Bim deletion polymorphism demonstrated a shorter PFS compared with those without it, with a median PFS of 83 days and 305 days, respectively , were the independent predictive factors in patients with ALK-positive disease who received crizotinib (Table 4 ). In addition, 4 patients with ALK-positive NSCLC without the Bim deletion polymorphism were unable to be evaluated for ALK variants due to the lack of adequate tumor specimens. Among 51 patients with ALK-positive NSCLC, the most common ALK variant was variant 1, which was found in 24 patients (47%); followed by variant 3a/b, which was noted in 18 patients (35%); variant 2, which was observed in 7 patients (14%); and other variants, which were observed in 2 patients (4%) (see Supporting Information Fig. 1 ). A total of 51 patients with ALK-positive disease were divided into ALK variant 1 and non-variant 1 groups based on the highest frequency of ALK variant 1 in patients with ALK-positive NSCLC. 36, 37 Supporting Information Table s2 shows the clinical characteristics according to the ALK variant status. There was no significant difference noted between ALK variant status and Bim polymorphism status (P 5 .778). It is interesting to note that we found that the ORRs of patients treated with crizotinib were 87.5% and 63.0%, respectively, in patients in the ALK variant 1 and non-variant 1 groups (P 5.045). However, as shown in Supporting Information Figure 2a , no significant difference in PFS was observed between patients in the ALK variant 1 and non-variant 1 groups (P 5.655). There were no differences in PFS observed between patients with and without the Bim deletion polymorphism in the ALK variant 1 group (P 5.066) and non-variant 1 group (P 5.230), respectively (see Figs. 2b and 2c) . With regard to the 14 patients with ROS1-positive disease, EZR-ROS1 fusion was observed in 7 patients, CD74-ROS1 fusion was observed in 4 patients, and SLC34A2-ROS1 fusion was observed in 3 patients (data not shown). Due to the limited number of patients with ROS1-positive disease, we were unable to investigate the relationship between the ROS1 fusion partners and Bim polymorphism status.
Supporting Information
DISCUSSION
To our knowledge, the current study is the first to investigate the relationship between the Bim deletion polymorphism and the effect of crizotinib in Chinese patients with ALK-positive or ROS1-positive NSCLC. The results of the current study demonstrated that no specific clinicopathologic feature was observed between patients with and without the Bim deletion polymorphism and indicated that the Bim deletion polymorphism was associated with poor ORR and a shorter PFS after treatment with crizotinib in patients with ALK-positive disease. Due to the limited number of patients with ROS1-positive NSCLC, the Bim deletion polymorphism was found to be associated with a shorter PFS but there was no statistically significant difference.
It is interesting to note that the Bim deletion polymorphism is a germline alteration and was most commonly observed in the East Asian population yet was absent in white individuals. 29 In the current study, the Bim deletion polymorphism was shown to occur in 9 patients with NSCLC with ALK or ROS1 gene rearrangement, with a prevalence of 13.0%, which was relatively consistent with most previous studies performed in unselected patients with NSCLC. [27] [28] [29] [38] [39] [40] In addition, all patients in the current study with the Bim deletion polymorphism were heterozygous. Previous studies have shown that the homozygous Bim deletion polymorphism was observed in patients with NSCLC. 26, 38, 39 However, we cannot conclude that the homozygous Bim deletion polymorphism was not present in patiefnts with ALK-positive or ROS1-positive NSCLC due to the limited number of cases. The results of the current study also indicated that the distribution of the Bim deletion polymorphism was random regardless of age, sex, smoking history, ECOG PS, histology, or stage of disease in patients with ALK-positive or ROS1-positive NSCLC.
In the current study, we observed a correlation between the Bim deletion polymorphism and an unfavorable response and short PFS after treatment with crizotinib in patients with ALK-positive NSCLC. As reported in previous studies, the Bim protein interacts with and regulates the proteins of the core BCL-2 family to activate cell death due to its proapoptotic BH3 domain. [21] [22] [23] Ng et al reported that a common intronic deletion polymorphism Abbreviations: ALK, anaplastic lymphoma kinase; Bim, B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (BCL2L11); ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer; ROS1, ROS proto-oncogene 1, receptor tyrosine kinase.
switched Bim, alternatively splicing from exon 4 to exon 3 using paired-end DNA sequencing, which led to the greater expression of Bim isoforms lacking the proapoptotic BH3 domain compared with cells without the deletion polymorphism; after treatment with EGFR TKIs, EGFR-mutant cells with the Bim deletion polymorphism were found to have decreased induction of BH3-containing Bim isoforms. 29 Correspondingly, numerous retrospective studies have demonstrated the association between the Bim deletion polymorphism and an inferior response to EGFR TKIs in patients with NSCLC with activating EGFR mutations. [26] [27] [28] [29] Thus, on the basis of previous studies and the results of the current study, we concluded that the Bim deletion polymorphism can lead to primary resistance and no response to TKIs in patients with ALK-positive disease. In addition, previous studies have shown that TKIs downregulate Bim expression directly through inhibition of the MEK-ERK pathway to trigger apoptosis in EGFR-mutant and ALK-positive lung cancer cell lines 24, 25, [41] [42] [43] ; furthermore, inhibition of Bim expression is sufficient to cause TKI resistance in vitro in EGFR-mutated cell lines. [41] [42] [43] Accordingly, patients with EGFR-mutant NSCLC who are treated with EGFR-TKIs with low expression levels of Bim in treatment-naive tumor biopsies were found to have an obvious shorter PFS than those individuals with high Bim expression. 44 Thus, patients with EGFR-mutated NSCLC with the Bim deletion polymorphism had relatively low expression of functional Bim, which results in resistance to EGFR TKIs. Further studies are needed to investigate whether the functional Bim RNA level could have a similar biological effect in patients with ALK-positive NSCLC.
Various mechanisms underlying acquired resistance have been observed in patients with ALK-positive disease who are treated with crizotinib. In approximately one-third of patients with crizotinib-resistant disease, the resistance is due to a secondary mutation within the ALK tyrosine kinase domain or copy number alterations of the ALK fusion gene. [14] [15] [16] 20 To overcome the issue of crizotinib resistance, several second-generation ALK inhibitors, such as ceritinib and alectinib, have been approved by the US Food and Drug Administration for the treatment of patients with ALK fusion-positive NSCLC. 9, 10 In addition, resistance also can be mediated by upregulation of bypass signaling pathways resulting in ALK-independent growth, such as the epidermal growth factor pathway, insulin-like growth factor pathway, mitogen-activated protein kinase (MAPK) pathway, SRC, KIT, and others. [17] [18] [19] Combination treatment with ALK inhibitors and agents against the activated receptor appears to be effective in preclinical studies to overcome the upregulation of bypass tracts. However, to our knowledge to date, the mechanisms of primary resistance to crizotinib therapy are not well understood. It is interesting to note that we put forward that the Bim deletion polymorphism can result in the primary resistance and no response to crizotinib for the first time. Some preclinical studies found that histone deacetylase inhibitors and BH3-mimetic drugs could overcome the Bim deletion polymorphismmediated EGFR-TKI resistance in patients with EGFRmutant lung cancer. 29, 45, 46 The addition of these drugs might improve the efficacy of crizotinib in patients with ALK-positive disease who are carrying the Bim deletion polymorphism. However, this is a single, central retrospective study. Well-designed prospective multicenter studies should be performed to demonstrate the correlation between the Bim deletion polymorphism and ALK inhibitors in patients with ALK-positive disease.
We must mention that there are several limitations to the current study. First, this was a retrospective study, and therefore selection bias was inevitable. Hence, the results of the current study need to be confirmed in prospective trials. Second, due to the limited number of patients included herein, the conclusions should be viewed with caution. Third, all enrolled patients harboring the Bim deletion polymorphism were heterozygous. To our knowledge to date, no homozygous carriers have been reported among patients with NSCLC with ALK or ROS 1 fusions. Future research will continue to increase the population in the hope of reducing the bias to some extent and of identifying homozygous Bim polymorphism carriers.
The results of the current study suggested that the Bim deletion polymorphism was associated with poor ORR and shorter PFS in patients with ALK-positive NSCLC who were treated with crizotinib. The Bim deletion polymorphism was found to be an independent predictive factor of shorter PFS among patients with ALK-positive NSCLC who were treated with crizotinib. However, more work should be conducted to investigate 
